NCT00134953View on ClinicalTrials.gov

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

PHASE3TerminatedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

May 31, 2004

Conditions

Cognitive Symptoms

Interventions

DRUG

Rivastigmine

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY